CT-P13 biosimilar is non-inferior to infliximab

Anti-TNF therapy is effective in IBD but the high costs of some biologic agents necessitate the development of biosimilar drugs. CT-P13 is a biosimilar of the anti-TNF agent infliximab and has been approved for patients with IBD on the basis of extrapolation in other indications, but a direct comparison of infliximab with a biosimilar for patients with IBD was lacking. Now, in a phase III randomized controlled trial, 220 patients with Crohn’s disease and naive to biologic agents were allocated to groups receiving CT-P13 or infliximab for 1 year, with a switch in therapy at week 30. After 6 weeks, the proportion of patients with a ≥70-point decrease in Crohn’s Disease Activity Index scores were similar in groups receiving CT-P13 or infliximab, establishing non-inferiority for CT-P13. Over the full study period, treatment-emergent adverse events were also similar between the groups.


Original article

  1. Ye, B. D. et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393, 1699–1707 (2019)

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Iain Dickson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. CT-P13 biosimilar is non-inferior to infliximab. Nat Rev Gastroenterol Hepatol 16, 326 (2019). https://doi.org/10.1038/s41575-019-0155-5

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing